LATEST ISSUES

view more
September 2024 - PharmaTimes
PharmaTimes

September 2024 - PharmaTimes

And, so, here we are – Keir we are, if you will. A brave new era nationally translates to an interesting adventure for both pharma and wider healthcare. This month we go big on the reality of political, infrastructural and institutional change. This edition also focuses on the all-encompassing, ever-evolving spectre of AI – what it is, what it wants and how it can be shaped meticulously into a force for good.

July 2024 - PharmaTimes
PharmaTimes

July 2024 - PharmaTimes

As the front cover so boldly suggests, this edition of PharmaTimes is at the ballot box! Indeed, we are pondering a future seems oddly elusive in spite of its alarming proximity! This is a very good reason for us to discuss the great themes of our time – who will take a country out of the debris of the last decade, what will become of our decrepit NHS, can we ever become best friends with AI, how can we ignite diversity throughout industry and, of course, how we can we make patient involvement vibe part of everyday pharma?

June 2024 - PharmaTimes
PharmaTimes

June 2024 - PharmaTimes

This issue is about the shaping, delivery and future of clinical trials – the exciting dawn of a new era for how therapies reach the marketplace. We cover the influence of digital, the radical shift in trial design and, above all, the need to incorporate patients at every stage. We’ve also got a review of our International Clinical Researcher of the Year bash – an unforgettable 25th edition of the enduring event. In addition, this issue looks at the influence of Florence Nightingale as an ace healthcare communicator, the future of unlicenced meds and the emerging involvement of AI across the life sciences.

May 2024 - PharmaTimes
PharmaTimes

May 2024 - PharmaTimes

This month we’re going places and – as our cover so boldly suggests – those places invite parity and equity. Women in pharma is a movement which not only yields a fair and more interesting pharmaverse, it ignites possibilities and propels performance. The edition of PharmaTimes you are about to peruse holds this reality aloft and parades it around our industry. We’ve also got a host of other features which demonstrate the rapid evolution of the life sciences including – the future of pharma, emerging novel therapies, taking on rare diseases and the continuing need to ensure a career in pharma is open to everyone.

April 2024 - PharmaTimes
PharmaTimes

April 2024 - PharmaTimes

Hope springs in this edition of PharmaTimes! By looking robots directly in the eye, we demystify how AI is influencing pharma and wider healthcare – as a force for good. Meanwhile, intrepid community pharmacists step out of the shadows and into bolder new arenas, helping to unshackle the NHS in the process. There are also captivating features on realising net-zero, campaign launches, men’s health and the evolving digital age. In addition, we continue to celebrate how new perspectives from women are igniting our industry and blazing a trail for the next generation. Yep, we’re living our best lives…

March 2024 - PharmaTimes
PharmaTimes

March 2024 - PharmaTimes

PharmaTimes ventures into modern, progressive and inclusive terrain! Our cover story looks at how diversity in clinical trials is evolving and what has to be done to ignite it. Meanwhile, we look at the future of pharma through a very modern lens, at a time when our industry is entering a sustained chapter of change. With this considered, there are also features on the compelling influence of women in pharma, the spectre of AI, the health climate crisis and why Star Trek could influence emerging MedTech. Yes, this magazine is boldly visiting new, unchartered dimensions!

January/February 2024 - PharmaTimes
PharmaTimes

January/February 2024 - PharmaTimes

We peruse the priorities for 2024 – innovation, partnerships and a focus on unmet clinical needs. Meanwhile, we focus on the healthcare horoscope of politics, tech, data, public health and the rise of the patient. Hop on for the ride as we ask how the NHS will be reconstructed, if the success in hepatitis C elimination can be repeated in HIV, why gene therapy challenges must be embraced and if we can realise the potential of real-world data throughout industry.

article-category

NEWS: Treatments

News, 27 August 2024
article-category

NEWS: Research

News, 27 August 2024
article-category

NEWS: Collaborations

News, 27 August 2024
article-category

NEWS: Conditions

News, 27 August 2024
article-category

NEWS: Treatments

News, 30 June 2024
article-category

NEWS: Research

News, 30 June 2024

Features

view more
article-category

COVER STORY - Starmer times

Features, 27 August 2024
article-category

WOMEN IN PHARMA - Leading from the front

Features, 27 August 2024
article-category

POLITICS - Transition vamp

Features, 27 August 2024
article-category

MENTAL HEALTH - Life of brain

Features, 27 August 2024
article-category

DATA - The next hurdle

Features, 27 August 2024
article-category

An eye on AI

Features, 30 June 2024

Analysis

view more
article-category

BUSINESS INSIGHTS - Cloud moment

Analysis, 27 August 2024
article-category

THOUGHT LEADER - Engagement parties

Analysis, 27 August 2024
article-category

AI - GenAI heads up

Analysis, 27 August 2024
article-category

GENES - Weird science!

Analysis, 27 August 2024
article-category

EYES - Vision of the future

Analysis, 27 August 2024
article-category

GenAI out of the bottle

Analysis, 30 June 2024

Smart People

view more
article-category

AI - Us and it

SmartPeople, 27 August 2024
article-category

MEDICINES - Days of reckoning

SmartPeople, 27 August 2024
article-category

JOBS - Together in electric dreams

SmartPeople, 27 August 2024
article-category

Your moves

SmartPeople, 27 August 2024
article-category

Aspirational goals

SmartPeople, 30 June 2024
article-category

A story of our times

SmartPeople, 30 June 2024